TNF and rheumatoid arthritis: Given that RA likely represents a heterogeneous group of conditions with a similar phenotype, we believe IL-7 may be a good alternative therapeutic target for a specific subgroup of RA patients, and for those where a RANKL inhibitor or TNF-α inhibitor is not effective.